Different doses of esketamine combined with nerve block for laparoscopic cholecystectomy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086122

Enrollment

Unknown

Registered

2024-06-25

Start date

2024-06-25

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallbladder disease

Interventions

A:At the end of the operation, the patient underwent right transversus abdominis plane block (20ml of 0.25% ropivacaine) and bilateral rectus sheath block (20ml of 0.25% ropivacaine, 10ml on each side

B:At the end of the operation, the patient received right transversus abdominis plane block (20ml of 0.25% ropivacaine + 0.125mg/kg esketamine mixture) and bilateral rectus abdominis sheath block (20m

C:At the end of the operation, the patient received right transversus abdominis plane block (20ml of 0.25% ropivacaine + 0.25mg/kg esketamine mixture) and bilateral rectus abdominis sheath block (20ml

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) American Society of anesthesiologists (ASA) grade i~ii; (2) The age ranged from 18 to 70 years; (3) Patients undergoing elective laparoscopic cholecystectomy; (4) Body mass index, BMI)18~28kg/m²; (5) The patients and their families gave informed consent.

Exclusion criteria

Exclusion criteria: (1) Contraindications to nerve block (local anesthetic allergy, local or systemic infection, bleeding or abnormal coagulation function); (2) Contraindications to the use of esketamine (increased intracranial pressure, poorly controlled or untreated hypertension, hyperthyroidism, mental disorders, etc.) (3) History of chronic pain or long-term use of sedative, analgesic and antidepressant drugs; (4) Complicated with serious diseases of heart, brain, liver, kidney and other organs, mental disease, pregnancy and other medical history; (5) There is communication barrier and unable to cooperate with the researcher.

Design outcomes

Primary

Measure	Time frame
VAS scores at various time points after surgery;	—

Secondary

Measure	Time frame
Ramsay Sedation score at each time point after surgery;Bruggrmann comfort scales at each time point after surgery;Rescue times of postoperative analgesic drugs;PHQ-9 score;	—

Countries

China

Contacts

Public ContactDing Dengfeng

Shenzhen People's Hospital

df_ding@sina.com+86 137 6017 6629

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026